Documents Ym bio sciences corppres ash2012 dec 10 12

1. Corporate Presentation ASH 20121 YM Corporate Presentation | ASH 2012 2. Safe HarborThis presentation may contain forward-looking statements, which reflect the Companys…

Business YM BioSciences Corporate Presentation

1. Corporate Presentation Calendar Q2 20121 YM Corporate Presentation | Calendar Q2/2012 2. Safe HarborThis presentation may contain forward-looking statements, which reflect…

Documents Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in....

Slide 1 Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis…

Documents YM BioSciences CorpPres ASH2012 Dec 10 12

1. Corporate Presentation ASH 20121 YM Corporate Presentation | ASH 2012 2. Safe HarborThis presentation may contain forward-looking statements, which reflect the Companys…